OwlTail

Cover image of John C. Byrd

John C. Byrd

13 Podcast Episodes

Latest 6 Nov 2021 | Updated Daily

Weekly hand curated podcast episodes for learning

Episode artwork

John C. Byrd, MD - How I Think, How I Treat: BTK Inhibitors as a Centerpiece of Care for Hematologic Cancers

PeerView Oncology & Hematology CME/CNE/CPE Audio Podcast

Go online to PeerView.com/UVJ860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In PeerView’s latest “How I Think, How I Treat” webcast, leading experts, John C. Byrd, MD, Alexey V. Danilov, MD, PhD, and Nicole Lamanna, MD, explore the current evidence that underlies the use of first- and second-generation BTK inhibitors in diseases such as CLL, MCL, and others. They also share their personal insights and intra-institutional experiences in order to illustrate what the availability of BTK inhibitor therapy has meant for their practices. Learn how the experts have adapted to the BTK era! Upon completion of this activity, participants should be better able to: Describe the anticancer mechanisms of first- and second-generation BTK inhibitors, Cite updated guidelines and evidence surrounding the efficacy and safety of first- and second-generation BTK inhibitors in the management of B-cell cancers, including CLL and MCL, among others, Develop appropriate single-agent, sequential, or combination strategies using BTK inhibitors in the management of patients with B-cell malignancies, Manage the unique spectrum of adverse events associated with the use of BTK inhibitors in patients with B-cell cancer.

1hr 43mins

17 Aug 2020

Episode artwork

John C. Byrd, MD - How I Think, How I Treat: BTK Inhibitors as a Centerpiece of Care for Hematologic Cancers

PeerView Internal Medicine CME/CNE/CPE Video Podcast

Go online to PeerView.com/UVJ860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In PeerView’s latest “How I Think, How I Treat” webcast, leading experts, John C. Byrd, MD, Alexey V. Danilov, MD, PhD, and Nicole Lamanna, MD, explore the current evidence that underlies the use of first- and second-generation BTK inhibitors in diseases such as CLL, MCL, and others. They also share their personal insights and intra-institutional experiences in order to illustrate what the availability of BTK inhibitor therapy has meant for their practices. Learn how the experts have adapted to the BTK era! Upon completion of this activity, participants should be better able to: Describe the anticancer mechanisms of first- and second-generation BTK inhibitors, Cite updated guidelines and evidence surrounding the efficacy and safety of first- and second-generation BTK inhibitors in the management of B-cell cancers, including CLL and MCL, among others, Develop appropriate single-agent, sequential, or combination strategies using BTK inhibitors in the management of patients with B-cell malignancies, Manage the unique spectrum of adverse events associated with the use of BTK inhibitors in patients with B-cell cancer.

1hr 43mins

17 Aug 2020

Similar People

Episode artwork

John C. Byrd, MD - How I Think, How I Treat: BTK Inhibitors as a Centerpiece of Care for Hematologic Cancers

PeerView Oncology & Hematology CME/CNE/CPE Video Podcast

Go online to PeerView.com/UVJ860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In PeerView’s latest “How I Think, How I Treat” webcast, leading experts, John C. Byrd, MD, Alexey V. Danilov, MD, PhD, and Nicole Lamanna, MD, explore the current evidence that underlies the use of first- and second-generation BTK inhibitors in diseases such as CLL, MCL, and others. They also share their personal insights and intra-institutional experiences in order to illustrate what the availability of BTK inhibitor therapy has meant for their practices. Learn how the experts have adapted to the BTK era! Upon completion of this activity, participants should be better able to: Describe the anticancer mechanisms of first- and second-generation BTK inhibitors, Cite updated guidelines and evidence surrounding the efficacy and safety of first- and second-generation BTK inhibitors in the management of B-cell cancers, including CLL and MCL, among others, Develop appropriate single-agent, sequential, or combination strategies using BTK inhibitors in the management of patients with B-cell malignancies, Manage the unique spectrum of adverse events associated with the use of BTK inhibitors in patients with B-cell cancer.

1hr 43mins

17 Aug 2020

Episode artwork

John C. Byrd, MD - How I Think, How I Treat: BTK Inhibitors as a Centerpiece of Care for Hematologic Cancers

PeerView Heart, Lung & Blood CME/CNE/CPE Video Podcast

Go online to PeerView.com/UVJ860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In PeerView’s latest “How I Think, How I Treat” webcast, leading experts, John C. Byrd, MD, Alexey V. Danilov, MD, PhD, and Nicole Lamanna, MD, explore the current evidence that underlies the use of first- and second-generation BTK inhibitors in diseases such as CLL, MCL, and others. They also share their personal insights and intra-institutional experiences in order to illustrate what the availability of BTK inhibitor therapy has meant for their practices. Learn how the experts have adapted to the BTK era! Upon completion of this activity, participants should be better able to: Describe the anticancer mechanisms of first- and second-generation BTK inhibitors, Cite updated guidelines and evidence surrounding the efficacy and safety of first- and second-generation BTK inhibitors in the management of B-cell cancers, including CLL and MCL, among others, Develop appropriate single-agent, sequential, or combination strategies using BTK inhibitors in the management of patients with B-cell malignancies, Manage the unique spectrum of adverse events associated with the use of BTK inhibitors in patients with B-cell cancer.

1hr 43mins

17 Aug 2020

Most Popular

Episode artwork

John C. Byrd, MD - How I Think, How I Treat: BTK Inhibitors as a Centerpiece of Care for Hematologic Cancers

PeerView Heart, Lung & Blood CME/CNE/CPE Audio Podcast

Go online to PeerView.com/UVJ860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In PeerView’s latest “How I Think, How I Treat” webcast, leading experts, John C. Byrd, MD, Alexey V. Danilov, MD, PhD, and Nicole Lamanna, MD, explore the current evidence that underlies the use of first- and second-generation BTK inhibitors in diseases such as CLL, MCL, and others. They also share their personal insights and intra-institutional experiences in order to illustrate what the availability of BTK inhibitor therapy has meant for their practices. Learn how the experts have adapted to the BTK era! Upon completion of this activity, participants should be better able to: Describe the anticancer mechanisms of first- and second-generation BTK inhibitors, Cite updated guidelines and evidence surrounding the efficacy and safety of first- and second-generation BTK inhibitors in the management of B-cell cancers, including CLL and MCL, among others, Develop appropriate single-agent, sequential, or combination strategies using BTK inhibitors in the management of patients with B-cell malignancies, Manage the unique spectrum of adverse events associated with the use of BTK inhibitors in patients with B-cell cancer.

1hr 43mins

17 Aug 2020

Episode artwork

John C. Byrd, MD - How I Think, How I Treat: BTK Inhibitors as a Centerpiece of Care for Hematologic Cancers

PeerView Internal Medicine CME/CNE/CPE Audio Podcast

Go online to PeerView.com/UVJ860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In PeerView’s latest “How I Think, How I Treat” webcast, leading experts, John C. Byrd, MD, Alexey V. Danilov, MD, PhD, and Nicole Lamanna, MD, explore the current evidence that underlies the use of first- and second-generation BTK inhibitors in diseases such as CLL, MCL, and others. They also share their personal insights and intra-institutional experiences in order to illustrate what the availability of BTK inhibitor therapy has meant for their practices. Learn how the experts have adapted to the BTK era! Upon completion of this activity, participants should be better able to: Describe the anticancer mechanisms of first- and second-generation BTK inhibitors, Cite updated guidelines and evidence surrounding the efficacy and safety of first- and second-generation BTK inhibitors in the management of B-cell cancers, including CLL and MCL, among others, Develop appropriate single-agent, sequential, or combination strategies using BTK inhibitors in the management of patients with B-cell malignancies, Manage the unique spectrum of adverse events associated with the use of BTK inhibitors in patients with B-cell cancer.

1hr 43mins

17 Aug 2020

Episode artwork

John C. Byrd, MD - How I Think, How I Treat: BTK Inhibitors as a Centerpiece of Care for Hematologic Cancers

PeerView Clinical Pharmacology CME/CNE/CPE Video

Go online to PeerView.com/UVJ860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In PeerView’s latest “How I Think, How I Treat” webcast, leading experts, John C. Byrd, MD, Alexey V. Danilov, MD, PhD, and Nicole Lamanna, MD, explore the current evidence that underlies the use of first- and second-generation BTK inhibitors in diseases such as CLL, MCL, and others. They also share their personal insights and intra-institutional experiences in order to illustrate what the availability of BTK inhibitor therapy has meant for their practices. Learn how the experts have adapted to the BTK era! Upon completion of this activity, participants should be better able to: Describe the anticancer mechanisms of first- and second-generation BTK inhibitors, Cite updated guidelines and evidence surrounding the efficacy and safety of first- and second-generation BTK inhibitors in the management of B-cell cancers, including CLL and MCL, among others, Develop appropriate single-agent, sequential, or combination strategies using BTK inhibitors in the management of patients with B-cell malignancies, Manage the unique spectrum of adverse events associated with the use of BTK inhibitors in patients with B-cell cancer.

1hr 43mins

17 Aug 2020

Episode artwork

John C. Byrd, MD - How I Think, How I Treat: BTK Inhibitors as a Centerpiece of Care for Hematologic Cancers

PeerView Clinical Pharmacology CME/CNE/CPE Audio Podcast

Go online to PeerView.com/UVJ860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In PeerView’s latest “How I Think, How I Treat” webcast, leading experts, John C. Byrd, MD, Alexey V. Danilov, MD, PhD, and Nicole Lamanna, MD, explore the current evidence that underlies the use of first- and second-generation BTK inhibitors in diseases such as CLL, MCL, and others. They also share their personal insights and intra-institutional experiences in order to illustrate what the availability of BTK inhibitor therapy has meant for their practices. Learn how the experts have adapted to the BTK era! Upon completion of this activity, participants should be better able to: Describe the anticancer mechanisms of first- and second-generation BTK inhibitors, Cite updated guidelines and evidence surrounding the efficacy and safety of first- and second-generation BTK inhibitors in the management of B-cell cancers, including CLL and MCL, among others, Develop appropriate single-agent, sequential, or combination strategies using BTK inhibitors in the management of patients with B-cell malignancies, Manage the unique spectrum of adverse events associated with the use of BTK inhibitors in patients with B-cell cancer.

1hr 43mins

17 Aug 2020

Episode artwork

John C. Byrd, MD - BTK Inhibition as an Anti-Cancer Strategy: Exploring a Model for Modern Targeted Therapy in Hematologic Malignancies and Beyond

PeerView Internal Medicine CME/CNE/CPE Video Podcast

Go online to PeerView.com/EQY860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. This PeerView CME/CNE-certified activity—based on a live event conducted in a MasterClass format held in conjunction with the 2019 meeting of the AACR—discusses how Bruton tyrosine kinase (BTK) inhibitors effectively target aspects of B-cell receptor signaling and covers key evidence and clinical issues related to the use of BTK inhibitors in hematologic malignancies (including agent selection, potential combination regimens, and strategies for overcoming drug intolerance or resistance). The panel of experts uses a mix of hard science and practical insight to offer learners an in-depth look at how the BTK inhibitor experience became a model for the development of targeted therapies in cancer, while also exploring the future applications of this unique drug class. Upon completion of this activity, participants will be able to: Cite the biologic rationale and anti-cancer mechanisms of BTK inhibition, Summarize updated evidence on the safety and efficacy of first- and second-generation BTK inhibitors in the management of B-cell cancers, Integrate BTK inhibitor–based strategies into the management of patients with B-cell malignancies, including chronic lymphocytic leukemia and mantle cell lymphoma, Manage safety considerations in patients with B-cell malignancies who are receiving therapy with BTK inhibitors.

1hr 10mins

22 May 2019

Episode artwork

John C. Byrd, MD - BTK Inhibition as an Anti-Cancer Strategy: Exploring a Model for Modern Targeted Therapy in Hematologic Malignancies and Beyond

PeerView Oncology & Hematology CME/CNE/CPE Audio Podcast

Go online to PeerView.com/EQY860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. This PeerView CME/CNE-certified activity—based on a live event conducted in a MasterClass format held in conjunction with the 2019 meeting of the AACR—discusses how Bruton tyrosine kinase (BTK) inhibitors effectively target aspects of B-cell receptor signaling and covers key evidence and clinical issues related to the use of BTK inhibitors in hematologic malignancies (including agent selection, potential combination regimens, and strategies for overcoming drug intolerance or resistance). The panel of experts uses a mix of hard science and practical insight to offer learners an in-depth look at how the BTK inhibitor experience became a model for the development of targeted therapies in cancer, while also exploring the future applications of this unique drug class. Upon completion of this activity, participants will be able to: Cite the biologic rationale and anti-cancer mechanisms of BTK inhibition, Summarize updated evidence on the safety and efficacy of first- and second-generation BTK inhibitors in the management of B-cell cancers, Integrate BTK inhibitor–based strategies into the management of patients with B-cell malignancies, including chronic lymphocytic leukemia and mantle cell lymphoma, Manage safety considerations in patients with B-cell malignancies who are receiving therapy with BTK inhibitors.

1hr 10mins

22 May 2019

Loading